Allena Pharmaceuticals (ALNA) Stock Analysis

What Allena Pharmaceuticals does

Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe. Its primary therapeutic candidate, ALLN-346, is an innovative enzyme designed to break down urate. This treatment is specifically aimed at individuals experiencing hyperuricemia and gout, especially when these conditions coexist with advanced chronic kidney disease. Established in 2011, Allena Pharmaceuticals maintains its corporate headquarters in Newton, Massachusetts.

Key metrics

ETFs linked to ALNA

Broad-market and Healthcare sector ETFs an investor holding Allena Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ALNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Allena Pharmaceuticals?

Allena Pharmaceuticals trades under the ticker ALNA on NASDAQ.

Which exchange is ALNA listed on?

ALNA is listed on NASDAQ.

What sector does Allena Pharmaceuticals operate in?

Allena Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ALNA in a portfolio?

PortView shows ALNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.